KYIV. Feb 29 (Interfax-Ukraine) – Public joint-stock company Farmak (Kyiv), a pharmaceutical manufacturer, saw a 96.9% rise in net profit in 2015, reaching UAH 407.279 million.
The company has reported in the information disclosure system of the National Commission for Securities and the Stock Market of Ukraine, the company’s results will be discussed at a general meeting of its shareholders scheduled for March 31, 2016.
As was reported, in 2014, Farmak boosted sales by 26.1% from 2013, to UAH 2.5 billion, its net profit shrank by 29.7%, to UAH 206.854 million. In the first half of 2015, its net profit amounted to UAH 168.596 million.
Farmak produces up to 200 different medicines.
By 2020, the company plans to boost sales to $1 billion and reduce the share of its sales in Ukraine from 80% to 60% of total sales. The company plans to ensure 10% of its sales on well regulated markets of Eastern Europe and the CIS each.
In 2014, Farmak launched 19 new medicines on the basis of nine new generic names.
According to Proxima Research, Farmak’s share of the Ukrainian pharmaceutical market is 5.6%.
Filia Zhebrivska is Farmak’s ultimate beneficiary.
